Equities

Standard Chem & Pharm Co Ltd

1720:TAI

Standard Chem & Pharm Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)64.40
  • Today's Change0.50 / 0.78%
  • Shares traded272.13k
  • 1 Year change+1.26%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,2762,5992,989
Total Receivables, Net1,4191,4801,490
Total Inventory1,6151,3861,218
Prepaid expenses1039587
Other current assets, total5.56290.80
Total current assets5,4185,5895,784
Property, plant & equipment, net4,3594,1093,095
Goodwill, net174174162
Intangibles, net415161
Long term investments968844769
Note receivable - long term------
Other long term assets887282
Total assets11,18910,96810,095
LIABILITIES
Accounts payable643686624
Accrued expenses------
Notes payable/short-term debt8001,3501,358
Current portion long-term debt/capital leases832120
Other current liabilities, total845822713
Total current liabilities2,3712,8802,716
Total long term debt445419290
Total debt1,3281,7901,668
Deferred income tax848584
Minority interest2,8382,6822,458
Other liabilities, total152149206
Total liabilities5,8906,2155,753
SHAREHOLDERS EQUITY
Common stock1,7871,7871,787
Additional paid-in capital224220204
Retained earnings (accumulated deficit)3,2752,8622,461
Treasury stock - common------
Unrealized gain (loss)21(109)(89)
Other equity, total(7.45)(6.48)(21)
Total equity5,2994,7534,342
Total liabilities & shareholders' equity11,18910,96810,095
Total common shares outstanding179179179
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.